Emergent BioSolutions (EBS) Curent Deferred Tax Liability (2013 - 2014)
Emergent BioSolutions' (EBS) quarterly Curent Deferred Tax Liability came in at $88000.0 in Q3 2014, little changed quarter-over-quarter from $88000.0 in Q2 2014.
Emergent BioSolutions (EBS) Curent Deferred Tax Liability (2013 - 2014) Analysis & Trends
Emergent BioSolutions' Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $88000.0 for Q3 2014.
- On a quarterly basis, Curent Deferred Tax Liability changed N/A year-over-year to $88000.0 in Q3 2014; TTM through Sep 2014 was $88000.0, a N/A change from a year earlier, with the FY2013 full-year figure at $88000.0, changed N/A from the prior year.
- Curent Deferred Tax Liability was little changed at $88000.0 in Q3 2014 per EBS's latest filing, from $88000.0 in the prior quarter.
- Across five years, Curent Deferred Tax Liability topped out at $88000.0 in Q4 2013 and bottomed at $88000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 88,000.00 |
| Sep 30, 2014 | 88,000.00 |
| Jun 30, 2014 | 88,000.00 |
| Jun 30, 2014 | 88,000.00 |
| Mar 31, 2014 | 88,000.00 |
| Mar 31, 2014 | 88,000.00 |
| Dec 31, 2013 | 88,000.00 |
| Dec 31, 2013 | 88,000.00 |